Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (216 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (231 journals)
    - DENTISTRY (292 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (120 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (186 journals)
    - GERONTOLOGY AND GERIATRICS (136 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (138 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (167 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (157 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (153 journals)

ALLERGOLOGY AND IMMUNOLOGY (216 journals)                  1 2 | Last

Showing 1 - 200 of 216 Journals sorted alphabetically
Acta Microbiologica et Immunologica Hungarica     Full-text available via subscription   (Followers: 5)
Advances in Immunology     Full-text available via subscription   (Followers: 39)
AIDS Research and Therapy     Open Access   (Followers: 15)
Alergologia Polska : Polish Journal of Allergology     Full-text available via subscription   (Followers: 2)
Allergies     Open Access   (Followers: 2)
Allergo Journal     Full-text available via subscription   (Followers: 2)
Allergo Journal International     Hybrid Journal   (Followers: 2)
Allergologia et Immunopathologia     Full-text available via subscription   (Followers: 1)
Allergology International     Open Access   (Followers: 5)
Allergy     Hybrid Journal   (Followers: 50)
Allergy & Rhinology     Open Access   (Followers: 4)
Allergy and Asthma Proceedings     Full-text available via subscription   (Followers: 14)
Allergy, Asthma and Clinical Immunology     Open Access   (Followers: 26)
American Journal of Epidemiology     Hybrid Journal   (Followers: 220)
American Journal of Immunology     Open Access   (Followers: 23)
American Journal of Preventive Medicine     Hybrid Journal   (Followers: 29)
American Journal of Reproductive Immunology     Hybrid Journal   (Followers: 6)
American Journal of Rhinology and Allergy     Hybrid Journal   (Followers: 9)
Annals of Allergy, Asthma and Immunology     Hybrid Journal   (Followers: 14)
Annals of Allergy, Asthma, and Immunology     Hybrid Journal  
Annual Review of Immunology     Full-text available via subscription   (Followers: 51)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 5)
Applied Immunohistochemistry & Molecular Morphology     Hybrid Journal   (Followers: 17)
Archives of Asthma, Allergy and Immunology     Open Access  
Archivum Immunologiae et Therapiae Experimentalis     Hybrid Journal   (Followers: 2)
Autoimmune Diseases     Open Access   (Followers: 3)
Autoimmunity     Hybrid Journal   (Followers: 9)
Autoimmunity Highlights     Open Access   (Followers: 2)
Autoimmunity Reviews     Hybrid Journal   (Followers: 3)
BMC Immunology     Open Access   (Followers: 11)
Cancer Immunology, Immunotherapy     Hybrid Journal   (Followers: 22)
Case Reports in Immunology     Open Access   (Followers: 6)
Cellular & Molecular Immunology     Hybrid Journal   (Followers: 15)
Cellular Immunology     Hybrid Journal   (Followers: 31)
Chronic Diseases and Injuries in Canada     Free   (Followers: 1)
Clinica Chimica Acta     Hybrid Journal   (Followers: 28)
Clinical & Experimental Allergy     Hybrid Journal   (Followers: 7)
Clinical & Experimental Allergy Reviews     Hybrid Journal   (Followers: 1)
Clinical & Experimental Immunology     Hybrid Journal   (Followers: 18)
Clinical & Translational Immunology     Open Access   (Followers: 8)
Clinical and Experimental Neuroimmunology     Hybrid Journal   (Followers: 1)
Clinical and Molecular Allergy     Open Access   (Followers: 5)
Clinical and Translational Allergy     Open Access   (Followers: 2)
Clinical Immunology     Hybrid Journal   (Followers: 25)
Clinical Immunology, Endocrine & Metabolic Drugs     Hybrid Journal  
Clinical Reviews in Allergy and Immunology     Hybrid Journal   (Followers: 12)
Comparative Immunology, Microbiology and Infectious Diseases     Hybrid Journal   (Followers: 14)
Critical Reviews in Immunology     Full-text available via subscription   (Followers: 15)
Current Allergy & Clinical Immunology     Open Access   (Followers: 8)
Current Allergy and Asthma Reports     Hybrid Journal   (Followers: 2)
Current Immunology Reviews     Hybrid Journal   (Followers: 10)
Current Opinion in Allergy and Clinical Immunology     Hybrid Journal   (Followers: 8)
Current Opinion in Immunology     Hybrid Journal   (Followers: 44)
Current Opinion in Virology     Hybrid Journal   (Followers: 1)
Current Protocols in Immunology     Hybrid Journal  
Current Treatment Options in Allergy     Hybrid Journal   (Followers: 2)
Developmental & Comparative Immunology     Hybrid Journal   (Followers: 7)
Egyptian Journal of Pediatric Allergy and Immunology     Open Access   (Followers: 2)
Emerging Infectious Diseases     Open Access   (Followers: 30)
Epidemiologic Methods     Hybrid Journal   (Followers: 4)
European Annals of Allergy and Clinical Immunology     Open Access   (Followers: 5)
European Journal of Immunology     Hybrid Journal   (Followers: 39)
European Journal of Microbiology and Immunology     Open Access   (Followers: 11)
Expert Review of Clinical Immunology     Full-text available via subscription   (Followers: 5)
Expert Review of Vaccines     Full-text available via subscription   (Followers: 4)
Food and Agricultural Immunology     Open Access   (Followers: 2)
Frontiers in Immunology     Open Access   (Followers: 20)
Future Virology     Hybrid Journal   (Followers: 8)
Genes & Immunity     Hybrid Journal   (Followers: 8)
Global Journal of Allergy     Open Access   (Followers: 1)
Handbook of Systemic Autoimmune Diseases     Full-text available via subscription   (Followers: 2)
HLA Immune Response Genetics     Hybrid Journal  
HNO Nachrichten     Full-text available via subscription  
Human Immunology     Hybrid Journal   (Followers: 18)
Human Vaccines & Immunotherapeutics     Full-text available via subscription   (Followers: 2)
Hypersensitivity     Open Access   (Followers: 1)
Immunity     Full-text available via subscription   (Followers: 66)
Immunity & Ageing     Open Access   (Followers: 10)
Immunity, Inflammation and Disease     Open Access   (Followers: 6)
Immuno-analyse & Biologie Spécialisée     Full-text available via subscription   (Followers: 2)
Immunobiology     Hybrid Journal   (Followers: 9)
Immunoendocrinology     Open Access   (Followers: 1)
Immunogenetics     Hybrid Journal   (Followers: 6)
ImmunoHorizons     Open Access  
Immunologic Research     Hybrid Journal   (Followers: 6)
Immunological Investigations: A Journal of Molecular and Cellular Immunology     Hybrid Journal   (Followers: 2)
Immunological Medicine     Open Access  
Immunological Reviews     Hybrid Journal   (Followers: 27)
Immunology     Hybrid Journal   (Followers: 38)
Immunology & Cell Biology     Hybrid Journal   (Followers: 9)
Immunology and Allergy Clinics of North America     Full-text available via subscription   (Followers: 6)
Immunology and Immunogenetic Insights     Open Access   (Followers: 5)
Immunology and Infectious Diseases     Open Access   (Followers: 9)
Immunology Innovation     Open Access   (Followers: 2)
Immunology Letters     Hybrid Journal   (Followers: 13)
Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Immunome Research     Open Access   (Followers: 6)
ImmunoTargets and Therapy     Open Access   (Followers: 2)
Immunotherapy     Hybrid Journal   (Followers: 7)
Immunotoxicology of Drugs and Chemicals: an Experimental and Clinical Approach     Full-text available via subscription   (Followers: 1)
Indian Journal of Allergy, Asthma and Immunology     Open Access   (Followers: 1)
Infectious Diseases: Research and Treatment     Open Access   (Followers: 4)
Inflammation & Allergy - Drug Targets     Hybrid Journal   (Followers: 2)
Inmunología     Full-text available via subscription   (Followers: 2)
Innate Immunity     Hybrid Journal   (Followers: 7)
International Archives of Allergy and Immunology     Full-text available via subscription   (Followers: 1)
International Forum of Allergy & Rhinology     Hybrid Journal   (Followers: 4)
International Immunology     Hybrid Journal   (Followers: 3)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
International Journal of Immunological Studies     Hybrid Journal   (Followers: 1)
International Journal of Immunopathology and Pharmacology     Full-text available via subscription   (Followers: 2)
International Journal of Immunotherapy and Cancer Research     Open Access   (Followers: 1)
International Journal of Infectious Diseases     Open Access   (Followers: 10)
International Journal of Virology     Open Access   (Followers: 2)
International Reviews Of Immunology     Hybrid Journal   (Followers: 4)
Internet Journal of Rheumatology and Clinical Immunology     Open Access   (Followers: 5)
Iranian Journal of Allergy, Asthma and Immunology     Open Access  
Joint Commission Journal on Quality and Patient Safety     Hybrid Journal   (Followers: 40)
Journal des Anti-infectieux     Full-text available via subscription   (Followers: 2)
Journal of Allergy & Therapy     Open Access   (Followers: 2)
Journal of Clinical & Cellular Immunology     Open Access   (Followers: 3)
Journal of Vaccines & Vaccination     Open Access   (Followers: 4)
Journal of Allergy and Clinical Immunology     Hybrid Journal   (Followers: 31)
Journal of Allergy and Clinical Immunology : In Practice     Full-text available via subscription   (Followers: 13)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Asthma and Allergy     Open Access   (Followers: 8)
Journal of Autoimmunity     Hybrid Journal   (Followers: 15)
Journal of Cellular Immunotherapy     Open Access   (Followers: 4)
Journal of Clinical Immunology     Hybrid Journal   (Followers: 14)
Journal of Clinical Immunology and Immunopathology Research     Open Access   (Followers: 5)
Journal of General Virology     Full-text available via subscription   (Followers: 11)
Journal of Immune Based Therapies, Vaccines and Antimicrobials     Open Access   (Followers: 2)
Journal of Immunological Methods     Hybrid Journal   (Followers: 46)
Journal of Immunological Techniques in Infectious Diseases     Hybrid Journal   (Followers: 3)
Journal of Immunology     Full-text available via subscription   (Followers: 68)
Journal of Immunology and Clinical Microbiology     Open Access   (Followers: 2)
Journal of Immunology and Regenerative Medicine     Hybrid Journal   (Followers: 1)
Journal of Immunology Research     Open Access   (Followers: 9)
Journal of Immunotherapy     Hybrid Journal   (Followers: 7)
Journal of Immunotherapy Applications     Open Access  
Journal of Immunotoxicology     Open Access   (Followers: 3)
Journal of Infection Prevention     Hybrid Journal   (Followers: 16)
Journal of Infectious Diseases and Immunity     Open Access   (Followers: 8)
Journal of Innate Immunity     Open Access   (Followers: 6)
Journal of Medical Genetics and Genomics     Open Access   (Followers: 3)
Journal of Microbiology, Immunology and Infection     Open Access   (Followers: 9)
Journal of Neuroimmunology     Hybrid Journal   (Followers: 6)
Journal of NeuroVirology     Hybrid Journal   (Followers: 1)
Journal of Reproductive Immunology     Hybrid Journal   (Followers: 2)
Journal of the Pediatric Infectious Diseases Society     Hybrid Journal   (Followers: 11)
Journal of Translational Autoimmunity     Open Access   (Followers: 2)
Journal of Vaccines and Immunology     Open Access   (Followers: 1)
Medical Immunology     Open Access   (Followers: 20)
Medical Microbiology and Immunology     Hybrid Journal   (Followers: 7)
Microbiology and Immunology     Hybrid Journal   (Followers: 10)
Molecular Immunology     Hybrid Journal   (Followers: 17)
Mucosal Immunology     Hybrid Journal   (Followers: 6)
Nature Immunology     Full-text available via subscription   (Followers: 316)
Nature Reviews Immunology     Full-text available via subscription   (Followers: 301)
Neuroimmunology and Neuroinflammation     Open Access   (Followers: 3)
NeuroImmunoModulation     Full-text available via subscription   (Followers: 2)
Neurology : Neuroimmunology & Neuroinflammation     Open Access   (Followers: 4)
npj Vaccines     Hybrid Journal  
OA Immunology     Open Access  
Ocular Immunology & Inflammation     Hybrid Journal   (Followers: 9)
OncoImmunology     Full-text available via subscription   (Followers: 3)
Open Allergy Journal     Open Access  
Open Cancer Immunology Journal     Open Access  
Open Forum Infectious Diseases     Open Access   (Followers: 4)
Open Immunology Journal     Open Access  
Open Journal of Immunology     Open Access   (Followers: 5)
Open Virology Journal     Open Access  
Oral Microbiology and Immunology     Hybrid Journal   (Followers: 1)
Papillomavirus Research     Open Access  
Parasite Immunology     Hybrid Journal   (Followers: 3)
Pediatric Allergy and Immunology     Hybrid Journal   (Followers: 38)
Perspectives in Vaccinology     Open Access   (Followers: 1)
Photodermatology, Photoimmunology & Photomedicine     Hybrid Journal   (Followers: 3)
Polish Pneumonology and Allergology     Open Access   (Followers: 1)
Procedia in Vaccinology     Open Access   (Followers: 2)
Recent Patents on Inflammation & Allergy Drug Discovery     Hybrid Journal   (Followers: 2)
Research & Reviews : A Journal of Immunology     Full-text available via subscription   (Followers: 6)
Research Journal of Allergy     Open Access   (Followers: 3)
Research Journal of Immunology     Open Access   (Followers: 3)
Results in Immunology     Open Access   (Followers: 4)
Revista Alergia México     Open Access  
Revista Portuguesa de Imunoalergologia     Open Access   (Followers: 2)
Revue Française d'Allergologie     Full-text available via subscription   (Followers: 3)
Russian Journal of Infection and Immunity     Open Access   (Followers: 20)
Scandinavian Journal of Immunology     Hybrid Journal   (Followers: 10)
Science Immunology     Full-text available via subscription   (Followers: 17)
Self/Nonself - Immune Recognition and Signaling     Full-text available via subscription   (Followers: 2)
Seminars in Immunology     Hybrid Journal   (Followers: 13)
Seminars in Immunopathology     Hybrid Journal   (Followers: 3)
Signals     Open Access   (Followers: 1)
Sinusitis     Open Access   (Followers: 1)
South East European Journal of Immunology     Open Access  
Therapeutic Advances in Vaccines     Hybrid Journal   (Followers: 1)
Therapeutic Advances in Vaccines and Immunotherapy     Open Access  
Toxicology and Environmental Health Sciences     Hybrid Journal   (Followers: 6)

        1 2 | Last

Similar Journals
Journal Cover
Current Opinion in Allergy and Clinical Immunology
Journal Prestige (SJR): 1.244
Citation Impact (citeScore): 3
Number of Followers: 8  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 1528-4050 - ISSN (Online) 1473-6322
Published by LWW Wolters Kluwer Homepage  [299 journals]
  • Editorial introductions
    • Abstract: imageNo abstract available
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Editorial: Advances in drug hypersensitivity reactions
    • Authors: Blanca; Miguel; Whitaker, Paul
      Abstract: No abstract available
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Drug provocation testing: risk stratification is key
    • Authors: Garvey; Lene H.; Savic, Louise C.
      Abstract: imagePurpose of review This review aims to describe current best practice and recent advances in the use of risk stratification as a tool for drug provocation testing (DPT). In particular, we focus on the testing of unsubstantiated penicillin allergy labels.Recent findings The inherent risks of DPT are mitigated through careful selection of patients. A detailed history will elicit features of a potentially severe index reaction, as well as significant patient comorbidities which may increase the risks associated with DPT. Such patients require skin testing and/or in vitro testing prior to consideration for a DPT. However, there is increasing evidence that patients without these features may be able to proceed directly to DPT. This has been demonstrated extensively with unsubstantiated penicillin allergy labels, and a variety of risk stratification models have been employed to identify the ‘low-risk’ patient. Improved outcomes and reduced cost have been demonstrated with such models without compromising patient safety.Summary Risk stratification tools may enable well-tolerated and effective ‘delabelling’ of low-risk patients, with less demand on already scarce resources.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Drug hypersensitivity in HIV infection
    • Authors: Peter; Jonny; Choshi, Phuti; Lehloenya, Rannakoe J.
      Abstract: imagePurpose of review Immune-mediated adverse drug reactions (IM-ADRs) are many times more common in HIV-infected patients. Usual offending drugs include antiretroviral and antiinfectives, but the burden of specific drug IM-ADRs is population-specific; changing as new and fixed dose combinations enter the market, and drug-resistance patterns demand. This review considers recent literature on epidemiology, mechanisms, clinical management and prevention of IM-ADRs amongst persons living with HIV/AIDS.Recent findings Epidemiological studies continue to describe high rates of delayed hypersensitivity to known offenders, as well as similar reactions in preexposure prophylaxis. IM-ADRs to oral and injectable integrase strand transfer inhibitors are reported with expanding use. The clinical spectrum and management of IM-ADRs occurring in HIV-infected populations is similar to uninfected; with exceptions such as a recently described severe delayed efavirenz DILI with high mortality. Furthermore, the context can be unique, such as the lower than expected mortality in a Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) cohort from a HIV/TB high burden setting. Programmatic data showing the near complete elimination of Abacavir drug hypersensitivity syndrome following implementation of HLA-B57:01 screening is a stellar example of how prevention is possible with mechanistic insight.Summary IM-ADRs remain a challenge in persons living with HIV. The complexities posed by polypharmacy, overlapping drug toxicities, drug interactions, overlap of IM-ADRs with other diseases, limited alternative drugs, and vulnerable patients with advanced immunosuppression with high mortality, necessitate increased use of drug provocation testing, treat-through and desensitization strategies. There is an urgent need for improved diagnostics and predictive biomarkers for prevention, or to guide treat-through, rechallenge and desensitization approaches.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Making a diagnosis in severe cutaneous drug hypersensitivity reactions
    • Authors: Ardern-Jones; Michael R.; Mockenhaupt, Maja
      Abstract: imagePurpose of review Severe cutaneous adverse reactions (SCAR) are relatively uncommon but can be life-threatening. This review focuses on the nonanaphylactic (non-IgE-mediated) phenotypes of drug hypersensitivity, with specific reference to diagnosis and management of acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).Recent findings Here, we review recent guidelines on optimal supportive care as well as publications of interventional treatment for SJS/TEN, including various immunomodulating therapies, and management strategies for severe ocular disease with the use of amniotic membrane transplantation. In DRESS, long-term autoimmune sequelae are increasingly recognized and modify strategies for treatment of the acute episode. If the causative drug is not apparent from careful inspection of the drug exposure history, in-vitro diagnostics, HLA testing and skin testing before drug challenge testing may be considered and we present an algorithm for investigation of complex cases.Summary Careful phenotypic analysis of the increasingly complex recognized patterns of SCAR facilitates the enhancement in our understanding of T-cell mediated drug hypersensitivity and allows the improvement of in-vitro diagnostic testing to minimize patient exposure to test substances in all but a very limited number of cases, thereby enhancing safety.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Role of T cells in non-immediate drug allergy reactions
    • Authors: Gómez; E.; Ruano, M.; Somoza, M.L.; Fernández, J.; Blanca-López, N.
      Abstract: imagePurpose of review Nonimmediate drug hypersensitivity reactions (NI-DHR) constitute the most complex group of drug allergy, with many drugs involved. Both parent drugs and their reactive metabolites can be implicated. Although with some drugs the number of metabolites is limited, with others it is quite extensive and many still remain to be identified. The diagnostic approaches are insufficient for the diagnosis and realistic approaches that reproduce the pathological response are lacking.Recent findings A wider view has now been considered, with the inclusion of several mechanisms that may contribute to drug hypersensitivity reactions (DHR): the classical hapten hypothesis, the danger signal and the pharmacological interaction. Monitoring the acute response provides relevant information about the mechanisms involved, with the identification of a large number of genes that can be over-expressed or under-expressed in the acute phase of the response. Assessment of risk of developing reactions can be verified by HLA associations.Summary Further knowledge of these NI-DHR, including molecular genetics and transcriptomic analysis, has enabled a better understanding and management of these reactions.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • New phenotypes in hypersensitivity reactions to nonsteroidal
           anti-inflammatory drugs
    • Authors: Lee; Youngsoo; Shin, Yoo Seob; Park, Hae-Sim
      Abstract: imagePurpose of review Nonsteroidal anti-inflammatory drug (NSAID) is one of the most frequently prescribed medications in the medical field, and hypersensitivity to NSAID is a common adverse drug reaction encountered. However, NSAID hypersensitivity presents a variety of symptoms caused by diverse pharmacological and immunological mechanisms.Recent findings Owing to the heterogeneity of the disease, a new concept for the classification of NSAID hypersensitivity has recently been proposed to diagnose and manage NSAID hypersensitivity for personalized treatment. Acute and delayed reactions were distinguished in this classification, and identification of symptoms and speculation of putative mechanisms help physicians make the right diagnosis. NSAID-exacerbated respiratory disease is a noticeable phenotype of NSAID hypersensitivity that involves upper airway comorbidities (chronic rhinosinusitis with nasal polyps) as well as asthmatic features. The cutaneous phenotypes of NSAID hypersensitivity occur, and cross-reactivity with other types of NSAID should be considered in establishing a proper diagnosis. Hypersensitivity to a single NSAID can present urticaria/angioedema and anaphylaxis, in which an IgE-mediated immune response is suggested to be a prime mechanism. Management of NSAID hypersensitivity reactions includes avoidance, pharmacological treatment following standard guidelines, and aspirin desensitization.Summary The classification, diagnosis, and management of NSAID hypersensitivity should be individually reached by identifying its phenotype.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Cutaneous drug hypersensitivity: developments and controversies
    • Authors: Brockow; Knut; Pfützner, Wolfgang
      Abstract: imagePurpose of review Cutaneous drug hypersensitivity reactions (CDHRs) are a complicated area with multiple clinical manifestations and differential diagnoses, requiring differentiated diagnostic measurements and optimized therapeutic management.Recent findings Disseminated CDHRs to classical drugs can be classified by a simple algorithm, whereas chemotherapeuticals or biopharmaceuticals may show drug-specific and atypical clinical presentations. Controversies in drug hypersensitivity diagnosis exist about the benefit and accuracy of in-vitro tests. Although skin tests are the best means of detecting sensitization to drugs, methods have not been sufficiently standardized. The necessity for skin tests before performing drug provocation test (DPT) and of prolonged DPTs is discussed in selected patients. If a suspicion has been documented, β-lactam allergy should be excluded. The standard allergy diagnosis is done by an allergist. In case of urgent need because of an infection and low risk according to history, faster delabeling pathways have been developed. There is weak evidence that patients with mastocytosis may have a slightly increased risk of developing immediate-type drug hypersensitivity; however, if considerations are taken, drugs do not have to be withheld for this patient group. There is particular need for improved diagnostic measurements in patients with drug-induced severe cutaneous adverse reactions (SCARs), both identifying the offending drug and detecting individuals at risk. Further challenges encompass appropriate treatments during the acute as well as chronic phase of SCARs.Summary Recent literature has contributed to our understanding of clinical manifestations and existing controversies and future needs in this area.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Common and different roles of IL-4 and IL-13 in skin allergy and clinical
           implications
    • Authors: Roesner; Lennart M.; Zeitvogel, Jana; Heratizadeh, Annice
      Abstract: imagePurpose of review This review summarizes the mode of action of IL-4 and IL-13 in skin allergy, upcoming therapeutics and depicts key outcomes of the latest clinical trials.Recent findings Atopic dermatitis is considered to be one of the most common inflammatory skin disease in industrialized countries. Accompanied by strong pruritus, atopic dermatitis has a significant impact on quality of life in severely affected individuals. Aside from unspecific immunosuppressant medications, therapeutics targeting the key cytokines IL-4 and IL-13 and their downstream mediators are under development or have been approved just recently with outstanding potential.Summary The recent development of several biologics and small compounds has the potential to revolutionize the treatment of atopic dermatitis, and applying this set of state-of-the-art drugs will provide a unique chance to gain insights into this skin disorder, patient subgroups, and key inflammatory mediators.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Microbiome and skin biology
    • Authors: Lunjani; Nonhlanhla; Hlela, Carol; O’Mahony, Liam
      Abstract: imagePurpose of review The skin is home to a diverse milieu of bacteria, fungi, viruses, bacteriophages, and archaeal communities. The application of culture-independent approaches has revolutionized the characterization of the skin microbiome and have revealed a previously underappreciated phylogenetic and functional granularity of skin-associated microbes in both health and disease states.Recent findings The physiology of a given skin-niche drives the site-specific differences in bacterial phyla composition of healthy skin. Changes in the skin microbiome have consistently been associated with atopic dermatitis. In particular, Staphylococcus aureus overgrowth with concomitant decline in Staphylococcus epidermidis is a general feature associated with atopic dermatitis and is not restricted to eczematous lesions. Changes in fungal species are now also being described. Changes in the composition and metabolic activity of the gut microbiota are associated with skin health.Summary We are now beginning to appreciate the intimate and intricate interactions between microbes and skin health. Multiple studies are currently focused on the manipulation of the skin or gut microbiome to explore their therapeutic potential in the prevention and treatment of skin inflammation.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Highlights in allergic contact dermatitis 2018/2019
    • Authors: Johansen; Jeanne D.; Werfel, Thomas
      Abstract: imagePurpose of review The purpose was to highlight recent findings especially concerning new and old allergens, trends, diagnosis and causes of contact allergy.Recent findings Nickel is still the most frequent cause of contact allergy in women and piercings remain an important risk factor. Countries with a long history of regulation of contact allergens have the lowest level of contact allergy to nickel and chromium in Europe. Among the most frequent causes of fragrance contact allergy is terpenes, which are oxidized such as limonene, linalool and in some countries: geraniol. Methylisothiazolinone is still causing considerable problems due to hidden exposures. Acrylates are emerging allergens and 2-hydroxyethyl methacrylate has been included in the 2019 update of the baseline series, as many new cases are seen due to long-lasting nail polish based on acrylates and glue (isobornyl acrylate) in insulin pumps. More than 10 new allergens have been described, which need to be considered in diagnosing contact allergy.Summary Allergic contact dermatitis is a frequent problem, it also constitutes a challenge to diagnose due to many potential contact allergens. The main culprit allergens remain the same, new significant causes are found especially within acrylates.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Dupilumab after the 2017 approval for the treatment of atopic dermatitis:
           what's new and what's next'
    • Authors: van der Schaft; Jorien; Thijs, Judith L.; de Bruin-Weller, Marjolein S.; Balak, Deepak M.W.
      Abstract: imagePurpose of review The IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling new data regarding dupilumab published following the approval.Recent findings Daily clinical practice reports of dupilumab in atopic dermatitis are favorable and in line with the registration trials. Dupilumab does not appear to negatively affect pharmacokinetics of CYP450-metabolized drugs nor vaccination responses. Type 2 inflammation biomarkers in skin and serum are reduced following dupilumab treatment. Dupilumab increases the risk for conjunctivitis, especially with higher baseline atopic dermatitis severity and a history of conjunctivitis, but the underlying mechanisms are unknown. Favorable effects of dupilumab have been reported in treatment-recalcitrant hand eczema and prurigo nodularis cases; for allergic contact dermatitis and alopecia areata, there are conflicting responses to dupilumab, possible stemming from pathophysiological heterogeneity.Summary Daily practice data support the continued use of dupilumab for atopic dermatitis. The only safety signal is an increased risk for conjunctivitis; mechanistic studies into dupilumab-associated conjunctivitis should lead to risk mitigation strategies. Prospective, controlled evaluations are needed for dupilumab in hand eczema and prurigo nodularis. A precision medicine-driven drug-development approach is essential to assess dupilumab for diseases with heterogeneous pathophysiologies, such as alopecia areata and allergic contact dermatitis.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Eosinophilic esophagitis during sublingual and oral allergen immunotherapy
    • Authors: Cafone; Joseph; Capucilli, Peter; Hill, David A.; Spergel, Jonathan M.
      Abstract: imagePurpose of review The aim of this review is to discuss the current evidence regarding the development of eosinophilic esophagitis (EoE) in individuals undergoing oral and sublingual immunotherapy (SLIT) for both food and environmental allergens. Cumulative incidence of EoE in patients on allergen immunotherapy for peanut, milk, and egg is estimated.Recent findings De novo development of EoE in patients undergoing oral and SLIT has been demonstrated on the scale of case reports and prospective randomized trials. However, few individuals with EoE-like symptoms during immunotherapy undergo endoscopy, and the long-term outcomes of immunotherapy-associated EoE are unknown.Summary Evidence exists to suggest that allergen immunotherapy could place individuals at risk for the development of EoE, the true incidence of which may vary depending on antigen exposure and methods used to define the condition.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Second generation antihistamines: an update
    • Authors: Sánchez-Borges; Mario; Ansotegui, Ignacio J.
      Abstract: imagePurpose of review This article presents an update on the clinical pharmacology, mechanisms of action, and safety of second generation antihistamines (SGAHs).Recent findings Recent research has shown the efficacy and good tolerance of SGAHs supporting its indication as first line medications for the treatment of allergic rhinoconjunctivitis and urticaria.Summary The information contained in this review is relevant for the correct utilization of SGAHs by practicing physicians who take care of these highly prevalent clinical disorders.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Use of biologics in chronic sinusitis with nasal polyps
    • Authors: Wang; Chengshuo; Zhang, Luo
      Abstract: imagePurpose of review Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory condition with different endotypes between patients from eastern or western countries. Targeted biologics are currently used to treat CRSwNP, but the outcomes widely vary. This review focuses on the present use of biologics for treating CRSwNP.Recent findings Monoclonal biologics have been used as an innovative therapy for multiple allergic diseases and comorbid allergic conditions. Over the past several decades, numerous biomarkers have been investigated and were found to be closely correlated with CRSwNP, improving the understanding of inflammatory patterns and endotype classifications for CRSwNP and prompting discussion regarding the use of biologics in CRSwNP. Efficacies vary in reports of different research groups, but it has been found that patients with TH-2-driven inflammatory patterns respond better to the use of biologics than those with non-TH-2-driven CRSwNP. These findings suggest the importance and urgency of developing criteria for biologics in CRSwNP.Summary Precisely determining patient criteria, identifying treatment biomarkers based on endotyping for CRSwNP and determinations of contraindications for long-term utilization may be useful for optimizing treatment strategies and improving the therapeutic efficacy of biologics to achieve long-term control starting at early stages.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Treatable traits in chronic rhinosinusitis with nasal polyps
    • Authors: Heffler; Enrico; Malvezzi, Luca; Pirola, Francesca; Zieba, Natalia; Paoletti, Giovanni; Mercante, Giuseppe; Spriano, Giuseppe; Canonica, Giorgio Walter
      Abstract: imagePurpose of review Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory sinonasal disease that deserves a multidisciplinary precision medicine approach. In a precision medicine model, a more pragmatic approach taking in consideration disease features that are potentially treatable should be considered.Recent findings Several treatable traits in CRSwNP can be identified: from disease-related ones, to extra-ENT features, to behavioral and environmental factors. This review article summarizes primarily the recent findings of CRSwNP-related treatable traits and how they can be modified by given treatments.Summary The advent of biological agents acting directly to the endotype underlying CRSwNP pushes the scientific community to integrate clinical, surgical and immunological evaluations for each single patient; this naturally leads to the identification of specific treatable traits that can serve as possible outcomes for any single biological.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Biological treatments for severe asthma
    • Authors: Assaf; Sara M.; Hanania, Nicola A.
      Abstract: imagePurpose of review Asthma is a heterogenous disease associated with different phenotypes and endotypes. The unmet needs with severe asthma have led to the emergence of potential therapeutic targets beyond the existing therapies. Recently, several biologics were examined and some have now been approved to target T2 airway inflammation in patients with severe disease. We provide an overview of recently approved biologic, those which are emerging and highlight unmet needs in this area.Recent findings Multiple biologics targeting T2 high asthma are now available for clinical use in the appropriate groups of severe asthma. These target overlapping phenotypes, which include allergic and eosinophilic asthma. Available biologics were shown to improve outcomes that include the reduction of exacerbations and improvement of lung function. Some have also demonstrated improvement in patient-reported outcomes. Some of these biologics have also demonstrated beneficial effects on associated asthma comorbidities. Biomarkers help predict response to certain biologics, although only few currently exist. Emerging biologics blocking other pathways of airway inflammation are under development. Several small molecule antagonists and inhibitors are also in development. Biologics and therapies targeting T2 low or non-T2 asthma are needed.Summary Recently approved biologic therapies improve asthma outcomes in subset of patients. Future research to uncover better predictors of response can improve the precise approach to therapy of patients with severe disease.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Treatment of urticaria: a clinical and mechanistic approach
    • Authors: Kaplan; Allen P.
      Abstract: imagePurpose of review This manuscript describes the recommended therapy of chronic spontaneous urticaria based on our understanding of the pathogenesis of hive formation. Thus, the mechanism of action of each medication is elaborated in addition to a discussion of clinical utility.Recent findings The main drugs are antihistamines, omalizumab, and cyclosporine with a success rate of 40–55, 65–80, and 70–80%, respectively. Used in sequence, over 90% of patients can be successfully treated. The addition of omalizumab represents a major advance because of its efficacy, easy utility, and favorable side-effect profile. The interaction with IgE eliminates any reaction with antigens to which it might be directed, down regulates IgE receptors on mast cells and basophils, and leads to down-regulation of mast cell functions with amelioration of hives.Summary The use of antihistamines in high dosage (at least four times a day) is effective in close to half the patients with CSU. For antihistamine resistance, the use of omalizumab has revolutionized therapy of antihistamine-resistant cases because of its efficacy and excellent side-effect profile. If the response is insufficient, cyclosporine is the next choice. Patients should be monitored regarding any adverse effects on blood pressure or renal function. All these are far safer than extended use of corticosteroid.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Therapeutic approach of anaphylaxis
    • Authors: Tanno; Luciana Kase; Alvarez-Perea, Alberto; Pouessel, Guillaume
      Abstract: imagePurpose of review Anaphylaxis is a recognized cause of death in all ages, which requires prompt recognition and treatment. We here propose to review the current and new pharmacological treatment of anaphylaxis in the view of the new knowledge in the field that can support the quality practice and empower allergists and health professionals with new tools that can be used to treat symptoms and prevent anaphylaxis.Recent findings The recent description of phenotypes provides new insight and understanding into the mechanisms and causes of anaphylaxis through a better understanding of endotypes and application of precision medicine. Several biologic therapies and new devices are emerging as potential preventive treatment for anaphylaxis.Summary Adrenaline (epinephrine) is still the first-line treatment for any type of anaphylaxis and is recognized as the only medication documented to prevent hospitalizations, hypoxic sequelae and fatalities. β2-adrenergic agonists and glucagon remains as the second-line treatment of anaphylaxis, meanwhile glucocorticoids and antihistamines should be used only as third-line treatment. Their administration should never delay adrenaline injection in anaphylaxis. More intuitive adrenaline autoinjectors design and features are required as well as a worldwide availability of adrenaline autoinjectors. Biological drugs, such as omalizumab, have been used as therapeutic adjuvants as a preventive treatment of anaphylaxis, but cost-effectiveness should be considered individually. Understanding the specifications of underlying mechanisms can potentially support improvements in the patients’ allergological work-up and open the opportunity of developments of potential new drugs, such as biological agents. Expanding knowledge with regard to the presentation, causes, and triggers for anaphylaxis among healthcare providers will improve its diagnosis and management, increase patient safety, and decrease morbidity and mortality.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
  • Recombinant allergens for immunotherapy: state of the art
    • Authors: Zhernov; Yury; Curin, Mirela; Khaitov, Musa; Karaulov, Alexander; Valenta, Rudolf
      Abstract: imagePurpose of review More than 30 years ago, the first molecular structures of allergens were elucidated and defined recombinant allergens became available. We review the state of the art regarding molecular AIT with the goal to understand why progress in this field has been slow, although there is huge potential for treatment and allergen-specific prevention.Recent findings On the basis of allergen structures, several AIT strategies have been developed and were advanced into clinical evaluation. In clinical AIT trials, promising results were obtained with recombinant and synthetic allergen derivatives inducing allergen-specific IgG antibodies, which interfered with allergen recognition by IgE whereas clinical efficacy could not yet be demonstrated for approaches targeting only allergen-specific T-cell responses. Available data suggest that molecular AIT strategies have many advantages over allergen extract-based AIT.Summary Clinical studies indicate that recombinant allergen-based AIT vaccines, which are superior to existing allergen extract-based AIT can be developed for respiratory, food and venom allergy. Allergen-specific preventive strategies based on recombinant allergen-based vaccine approaches and induction of T-cell tolerance are on the horizon and hold promise that allergy can be prevented. However, progress is limited by lack of resources needed for clinical studies, which are necessary for the development of these innovative strategies.
      PubDate: Thu, 01 Aug 2019 00:00:00 GMT-
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 35.175.121.230
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-